Harrow Health Inc (HROW)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

12264 EL CAMINO REAL SAN DIEGO, CA 92130

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of non-invasive topically delivered medications. The company's lead topical drug candidate, Ketotransdel, utilizes its proprietary Transdel cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the epidermis and into underlying tissues. Ketotransdel provides an alternative to the oral administration of cyclooxygenase-2 selective NSAIDs (COX-2 inhibitors) and non-selective NSAIDs. It has completed a Phase 1/2 trial for treating soft tissue pain and soreness in a delayed onset muscle soreness model with Ketotransdel. Transdel Pharmaceuticals also investigates other drug candidates and treatments for transdermal delivery using Transdel technology, including anesthetics, human hormone replacement, and anti-nausea medications. The company was founded in 1998 and is headquartered in La Jolla, California.

Data based on most recent fiscal year report
Market Cap35.534 Million Shares Outstanding20.54 Million Avg Volume517.068 Thousand
1-Yr BETA vs S&P TR0.819 Current Ratio1.53 Quick Ratio1.14
View SEC Filings from HROW instead.
Q2 2019 All Institutions Hedge Funds 1
To trade HROW now:
Filers who had this stock in their top 10: 2 2 (0.21%)
13F Filers holding this stock: 53 14 (1.45%)
Aggregate 13F shares on 06/30/2019: 8.647 Million 5.007 Million
Aggregate 13F shares on 03/31/2019: 7.938 Million 4.615 Million
Percent change: 8.93% 8.49%
Funds creating new positions: 16 2
Funds Adding to an existing position: 10 3
Funds closing out their position: 17 5
Funds reducing their position: 18 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HROW (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

13 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KAMMER ROBERT J

  • Director
816,827 2019-08-12 13

BONFIGLIO JOHN N CHIEF OPERATING OFFICER

  • Officer
37,500 2019-07-01 0

AUSTIN STEPHEN G

  • Director
0 2019-06-26 1

LINDSTROM RICHARD L MD

  • Director
0 2019-06-26 1

PRINCIPI ANTHONY

  • Director
0 2019-06-26 1

THORNLEY ANTHONY S

  • Director
49,536 2019-05-07 0

SWANN LYNN C

  • Director
18,201 2019-05-02 0

BAUM MARK L

  • Director
0 2019-02-20 1

BOLL ANDREW R. CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-19 1

SAHAREK JOHN P. CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-02-19 1

LONGBOARD CAPITAL ADVISORS, LLC

CONRAD BRETT

  • 10% Owner
299,237 2018-10-22 0

KENNY PETER C

  • Director
8,600 2017-05-17 0

EDWARDS CLAYTON D CHIEF OPERATING OFFICER

  • Officer
0 2017-04-13 0

NELSON WILLIAM H.

  • Director
0 2016-06-10 0

OPALEYE MANAGEMENT INC.

  • 10% Owner
1,250,000 2016-03-11 0

MILONI DONALD PAUL

  • 10% Owner
No longer subject to file 2015-05-18 0

BASSANI AUGUST SHELBY

  • Director
13,488 2014-09-04 0

FINNEGAN PAUL

  • Director
6,865 2013-06-27 0

ABRAMS JEFFREY J

  • Director
45,927 2013-06-27 0

SCHUPP JOACHIM PH CHIEF MEDICAL OFFICER

  • Officer
0 2013-04-01 0

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA, INC.

  • 10% Owner
832,682 2012-08-31 0

DERMASTAR INTERNATIONAL, LLC

  • 10% Owner
0 2012-06-29 0

LADONNIKOV ALEXEJ

  • 10% Owner
1,984,156 2012-02-28 0

BRAR BALBIR

  • Director
66,022 2012-01-23 0

NIDA TERRY CHIEF BUSINESS OFFICER

  • Officer
0 2010-02-26 0

SINGH JULIET CEO, DIRECTOR AND PRESIDENT

  • Officer
  • Director
  • 10% Owner
0 2009-06-18 0

LOMORO JOHN T CHIEF FINANCIAL OFFICER

  • Officer
0 2009-06-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

KAMMER ROBERT J - Director

2019-08-12 S 6,500 $6.89 d 816,827 816,827.00 direct yes

KAMMER ROBERT J - Director

2019-07-15 S 6,500 $7.91 d 823,327 823,327.00 direct yes

AUSTIN STEPHEN G - Director

2019-06-26 A 9,715 a 9,715 0.00 direct

PRINCIPI ANTHONY - Director

2019-06-26 A 9,715 a 9,715 0.00 direct

LINDSTROM RICHARD L MD - Director

2019-06-26 A 9,715 a 9,715 0.00 direct

KAMMER ROBERT J - Director

2019-06-26 A 9,715 a 9,715 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments